EGFR and non-small cell lung carcinoma: The first-generation reversible EGFR TKIs gefitinib (Iressa®, AstraZeneca, Wilmington, DE) 2 and erlotinib (Tarceva®, Genentech, South San Francisco, CA) 4 were the first EGFR-directed therapies to be approved by the FDA in NSCLC.